Iron metabolism in solid-organ transplantation: How far are we from solving the mystery?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 10, 2012, Pages 504-511

  Małyszko, Jolanta ^a   Levin Iaina, Nomy ^b   Myśliwiec, Michał ^a   Przybyłowski, Piotr ^c   Durlik, Magdalena ^d  

^a Samodzielny Publiczny Dzieci cy Szpital Kliniczny   (Poland)

^b SHEBA MEDICAL CENTER   (Israel)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Ferritin; Heart; Hepcidin; Iron metabolism; Liver transplantation

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; TRANSFERRIN;

ANEMIA; CHRONIC KIDNEY DISEASE; ERYTHROPOIESIS; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IRON BINDING CAPACITY; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MORTALITY; PROTEIN EXPRESSION; REVIEW;

EID: 84868662363     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1423     Document Type: Review

References (129)

1. Brittenham, GM. Disorders of iron metabolism: iron deficiency and overload. In: Hematology Basic Principles and Practice. 2nd ed. Hoffman R, Benz EJ Jr, Shattil SJ, et al., (eds). Churchill Livingstone, New York; 1995: 481.
2. Bridges KR, Seligman PA. Disorders of iron metabolism. In: Blood: Principles & Practice of Hematology. Handin RI, Lux E, Stossel TP (eds). Lippincott, United States; 1995: 1-428.
3. Roy CN, Enns CA. Iron homeostasis: new tales from the crypt. Blood. 2000; 96: 4020-4027.
4. Philpott CC. Molecular aspects of iron absorption: Insights into the role of HFE in hemochromatosis. Hepatology. 2002; 35: 993-1001. (Pubitemid 34453996)
5. Beaumont C, Beris P, Beuzard Y, Brugnara C. Disorders of erythropoiesis, erythrocytes and iron metabolism. Forum Service Editore, Genoa, Italy 2009. ISBN 978-88-89 620-13-7.
6. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102: 783-738.
7. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005; 106: 2884-2809.
8. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41: 482-487.
9. Truksa J, Gelbart T, Peng H, et al. Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/ TMPRSS6. Br J Haematol. 2009; 147: 571-581.
10. Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008; 8: 502-511.
11. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007; 13: 1096-1101. (Pubitemid 47517510)
12. Ramirez JM, Schaad O, Durual S, et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol. 2009; 144: 251-262.
13. Lakhal S, Talbot NP, Crosby A, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood. 2009; 113: 1555-1563.
14. Andrews NC. Molecular control of iron metabolism. Best Practice Res Clin Hematol. 2005; 18: 159-169. (Pubitemid 40298362)
15. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med. 1982; 306: 1520-1528. (Pubitemid 12123933)
16. Cook JD. Clinical evaluation of iron deficiency. Semin Hematol. 1982; 19: 6-18.
17. Bothwell TH. Overview and mechanisms of iron regulation. Nutr Rev. 1995: 53: 237-245.
18. Worwood M. Overview of iron metabolism at a molecular level. J Intern Med. 1989; 226: 381-391. (Pubitemid 19269643)
19. Deaglio S, Capobianco A, Cali A, et al. Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood. 2002; 100: 3782-3789. (Pubitemid 35303952)
20. Robb, A, Wessling-Resnick, M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood. 2004; 104: 4294-4299. (Pubitemid 39620185)
21. Kawabata H, Nakamaki T, Ikonomi P, et al. Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood. 2001; 98: 2714-2719.
22. Johnson MB, Enns CA. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood. 2004; 104: 4287-4293. (Pubitemid 39620184)
23. Finch CA, Bellotti V, Stray S. Plasma ferritin determination as a diagnostic tool. West J Med. 1986; 145: 657-663. (Pubitemid 17196113)
24. Cook JD, Boy E, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood. 2003; 101: 3359-3363.
25. Fernández-Rodríguez AM, Guindeo-Casasús MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis. 1999; 34: 508-513. (Pubitemid 29413624)
26. Jensen PD. Evaluation of iron overload. Br J Haematol. 2004; 124: 697-711.
27. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Eng J Med. 1993; 328: 1616-1620. (Pubitemid 23151923)
28. Pippard MJ. Detection of iron overload. Lancet. 1997; 349: 73-74. (Pubitemid 27023419)
29. Milman N. Iron status markers in hereditary haemochromatosis: distinction between individuals being homozygous and heterozygous for the haemochromatosis allele. Eur J Haematol. 1991; 47: 292-298.
30. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001; 33: 940-959. (Pubitemid 32706687)
31. Dey R, Datta SC. Leishmanial glycosomes contain superoxide dismutase. Biochem J. 1994; 301: 317-319. (Pubitemid 24231928)
32. Zhang Y, Lathigra R, Garbe T, et al. Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis. Mol Microbiol. 1991; 5: 381-391. (Pubitemid 21896057)
33. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature. 2002; 417: 552-555. (Pubitemid 34595922)
34. Risso A. Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leukoc Biol. 2000; 68: 785-792.
35. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101: 2461-2463. (Pubitemid 36857598)
36. Yang D, Biragyn A, Hoover DM, et al. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004; 22: 181-215. (Pubitemid 38680422)
37. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102: 783-788. (Pubitemid 36917762)
38. Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002; 100: 3776-3781. (Pubitemid 35303951)
39. Al Younes HM, Rudel T, Brinkmann V, et al. Low iron availability modulates the course of Chlamydia pneumoniae infection. Cell Microbiol. 2001; 3: 427-437. (Pubitemid 32600456)
40. Schaible UE, Collins HL, Priem F, Kaufmann SH. Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med. 2002; 196: 1507-1513. (Pubitemid 35424944)
41. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis. 1999; 5: 346-352. (Pubitemid 29289448)
42. Muñoz P, Fernández NS, Fariñas MC. Epidemiology and risk factors of infections after solid organ transplantation. Enferm Infecc Microbiol Clin. 2012; 30 Suppl 2: 10-18.
43. Pacholczyk M, Lagiewska B, Lisik W, et al. Invasive fungal infections following liver transplantation - risk factors, incidence and outcome. Ann Transplant. 2011; 16: 14-16.
44. Cervera C, Fernández-Ruiz M, Valledor A, et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. Transpl Infect Dis. 2011; 13: 598-607.
45. Alexander J, Limaye AP, Ko CW, et al. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl. 2006; 12: 1799-1804. (Pubitemid 44911806)
46. Theurl I, Fritsche G, Ludwiczek S, et al. The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections. Biometals. 2005; 18: 359-367. (Pubitemid 41298020)
47. Schrettl M, Bignell E, Kragl C, et al. Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J Exp Med. 2004; 200: 1213-1219. (Pubitemid 39507061)
48. Oexle H, Kaser A, Most J, et al. Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells. J Leukoc Biol. 2003; 74: 287-294. (Pubitemid 38040426)
49. van Asbeck BS, Marx JJ, Struyvenberg A, et al. Effect of iron (III) in the presence of various ligands on the phagocytic and metabolic activity of human polymorphonuclear leukocytes. J Immunol. 1984; 132: 851-856. (Pubitemid 14183688)
50. Weiss G, Umlauft F, Urbanek M, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis. 1999; 180: 1452-1458. (Pubitemid 29506445)
51. Schaible U, Kaufmann S. Iron and microbial infection. Nat Rev Microbiol. 2004; 4: 946-953. (Pubitemid 39562533)
52. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol. 1998; 9: 655-663. (Pubitemid 28186054)
53. Singh N, Sun HY. Iron overload and unique susceptibility of liver transplant recipients to disseminated disease due to opportunistic pathogens. Liver Transpl. 2008; 14: 1249-1255.
54. Ashrafian H. Hepcidin: the missing link between hemochromatosis and infections. Infec Immun. 2003; 71: 6693-6700. (Pubitemid 37475295)
55. Davis JW, Sizemore RK. Incidence of Vibrio species associated with blue crabs (Callinectes sapidus) collected from Galveston Bay, Texas. Appl Environ Microbiol. 1982; 43: 1092-1097.
56. Tamplin M, Rodrick GE, Blake NJ, Cuba T. Isolation and characterisation of Vibrio vulnificus from two Florida estuaries. Appl Environ Microbiol. 1992; 44: 1466-1470.
57. Strom MS, Paranjpye RN. Epidemiology and pathogenesis of Vibrio vulnificus. Microbes Infect. 2000; 2: 177-188. (Pubitemid 30154707)
58. Levine WC, Griffin PM. Vibrio infections on the Gulf Coast: results from first regional surveillance. Gulf Coast Vibrio Working Group. J Infect Dis. 1993; 167: 479-483. (Pubitemid 23036459)
59. Skaar EP, Humayun M, Bae T, et al. Iron-source preference of Staphylococcus aureus infections. Science. 2004; 305: 1626-1628. (Pubitemid 39296358)
60. Rouault TA. Pathogenic bacteria prefer heme. Science. 2004; 305: 1577-1578. (Pubitemid 39296344)
61. Eisendle M, Oberegger H, Zadra I, Haas H. The siderophore system is essential for viability of Aspergillus nidulans: functional analysis of two genes encoding l-ornithine N5-monooxygenase (sidA) and a non-ribosomal peptide synthetase (sidC). Mol Microbiol. 2003; 49: 359-375. (Pubitemid 36851193)
62. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993; 91: 1979-1986. (Pubitemid 23141469)
63. Howard DH. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev. 1999; 12: 394-404. (Pubitemid 29330136)
64. Crowe WE, Maglova LM, Ponka P, Russell JM. Human cytomegalo-virus-induced host cell enlargement is iron dependent. Am J Physiol Cell Physiol. 2004; 287: C1023-C1030. (Pubitemid 39238326)
65. Romeo AM, Christen L, Niles EG, Kosman DJ. Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J Biol Chem. 2001; 276: 24 301-24 308.
66. van Asbeck BS, Georgiou NA, van der Bruggen T, et al. Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol. 2001; 20: 141-147. (Pubitemid 32106870)
67. Kartikasari AE, Georgiou NA, de Geest M, et al. Iron enhances endothelial cell activation in response to Cytomegalovirus or Chlamydia pneumoniae infection. Eur J Clin Invest. 2006; 36: 743-752. (Pubitemid 44393934)
68. Haririan A, Morawski K, West MS, et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant. 2007; 21: 466-471. (Pubitemid 47161822)
69. Marty F, Bryar J, Browne S, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007; 110: 490-500. (Pubitemid 47105386)
70. Ammendolia M, Marchetti M, Superti F. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monley Kidney cells. Antivir Res. 2007; 76: 252-262. (Pubitemid 47600359)
71. Farigon S, Fracabzani AL, Sampietro M, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C Eur J Gastroenterol Hepatol. 1997; 9: 497-503. (Pubitemid 27214456)
72. Piperno A, Sampietro M, D'Alba R, et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver. 1996; 16: 248-254. (Pubitemid 26290234)
73. Kulaksiz H, Gehrke SG, Janetzko A, et al. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut. 2004; 53: 735-743. (Pubitemid 38561454)
74. Malyszko J, Malyszko JS, Koc-Zorawska E, et al. Neutrophil gelatinase-associated lipocalin in dialyzed patients is related to residual renal function, type of renal replacement therapy and inflammation. Kidney Blood Press Res. 2009; 32: 464-469.
75. Malyszko J, Malyszko JS, Kozminski P, et al. Possible relationship between neutrophil gelatinase-associated lipocalin, hepcidin, and inflammation in haemodialysed patients. Nephron Clin Pract. 2010; 115: c268-c275.
76. Mix TC, Kazmi W, Khan S, et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant. 2003; 3: 1426-1433. (Pubitemid 37288089)
77. Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant. 2002; 2: 429-435. (Pubitemid 36306883)
78. Moore J, He X, Cockwell P, et al. The impact of hemoglobin levels on patient and graft survival in renal transplant recipients. Transplantation. 2008; 86: 564-570.
79. Shibagaki Y, Shetty A. Anemia is common after kidney transplantation, especially among African Americans. Nephrol Dial Transplant. 2004; 19: 2368-2373. (Pubitemid 39214135)
80. Lorenz M, Kletzmayr J, Perschl A, et al. Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol. 2002; 13: 794-797. (Pubitemid 34183948)
81. Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation. 2006; 810: 1112-1118.
82. Zheng S, Coyne DW, Joist H, et al. Iron deficiency anemia and iron losses after renal transplantation. Transpl Int. 2009; 22: 434-440.
83. Jimeno L, Rodado R, Campos M, Lanuza M. Iron deficiency - an underrecognized problem in nonanemic and erythrocytic kidney transplant recipients: risks and effects of ACEI and of iron treatment. Transplant Proc. 2005; 37: 1007-1008. (Pubitemid 40590775)
84. Przybylowski P, Malyszko J, Glowinska I, et al. Prevalence of iron deficiency in heart and kidney allograft recipients. Transplant Proc. 2011; 43: 3885-3887.
85. Mudge DW, Tan KS, Miles R, et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation. 2012; 93: 822-826.
86. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin iron in disorders of iron metabolism. Transfusion Sci. 2000; 23: 185-192.
87. Salonen JT, Nyyssönen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992; 86: 803-811.
88. Tielemans CL, Lenclud CM, Wens R, et al. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant. 1989; 4: 883-887. (Pubitemid 20031057)
89. Espósito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2002; 32 Suppl 1: 42-49. (Pubitemid 41704987)
90. Malyszko J, Glowinska I, Malyszko JS, et al. Iron metabolism in kidney allograft recipients: still a mystery? Transplant Proc. 2011; 43: 2973-2975.
91. Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003; 87: S24-S31. (Pubitemid 37315504)
92. Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail. 2011; 4: 599-606.
93. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011; 58: 1241-1251.
94. Macdougall IC, Canaud B, de Francisco AL, et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail. 2012; 14: 882-886.
95. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010; 31: 1872-1880.
96. Przybylowski P, Malyszko J, Malyszko JS, et al. Anemia in heart and kidney allograft recipients: is there a role for hepcidin? Transplant Proc. 2010; 42: 4255-4258.
97. Przybylowski P, Malyszko JS, Macdougall IC, et al. Iron metabolism, hepcidin and anemia in orthotopic heart transplantation treated with mTOR. Transplant Proc. 2012. In press.
98. Maiorano A, Stallone G, Schena A, et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation. 2006; 82: 908-912. (Pubitemid 44564036)
99. McDonald MA, Gustafsson F, Almasood A, et al. Sirolimus is associated with impaired hematopoiesis in heart transplant patients? A retrospective analysis. Transplant Proc. 2010; 42: 2693-2696.
100. Müller HM, Horina JH, Kniepeiss D, et al. Characteristics and clinical relevance of chronic anemia in adult heart transplant recipients. Clin Transplant. 2001; 15: 343-348. (Pubitemid 32936882)
101. Przybylowski P, Malyszko J, Levin-Iaina N, Malyszko JS. Lack of non-transferrin-bound iron in heart transplant recipients. Transplant Proc. 2011; 43: 3068-3070.
102. Przybylowski P, Koc-Zorawska E, Glowinska I, et al. Hemojuvelin and iron metabolism in kidney and heart allograft recipients. Transplant Proc. 2012. In press.
103. Przybylowski P, Malyszko J, Malyszko JS. A possible role of hepcidin in the pathogenesis of anemia in heart allograft recipients. Transplant Proc. 2010; 42: 1803-1807.
104. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Eng J Med. 2003; 349: 931-940. (Pubitemid 37064766)
105. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998; 66: 59-66. (Pubitemid 28341169)
106. A comparison of tacrolimus (FK 506) and cyclosporine for immuno-suppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Eng J Med. 1994; 331: 1110-1115.
107. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001; 72: 1934-1939. (Pubitemid 34027867)
108. Malyszko J, Durlik M, Przybylowski P. Kidney dysfunction after non renal solid organ transplantation. Ann Transplant. 2009; 14: 71-79.
109. Fikatas P, Ulrich F, Lee JE et al. The APACHE III score as preoperative indicator of patient outcome in liver transplantation after fulminant hepatic failure. Ann Transplant. 2011; 16: 18-25.
110. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006; 38: 531-539.
111. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41: 482-487.
112. Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009; 41: 478-481.
113. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004; 36: 77-82. (Pubitemid 38056211)
114. Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008; 112: 1503-1509.
115. Zhang AS, Anderson SA, Wang J, et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood. 2011; 117: 1687-1699.
116. Tung BY, Farrell FJ, McCashland TM, et al. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl. 1999; 5: 369-374. (Pubitemid 29437013)
117. Keeffe EB. Liver transplantation in patients with hepatic iron overload: favorable or unfavorable outcome? Hepatology. 2000; 32: 1396-1398.
118. Singh N, Wannstedt C, Keyes L, et al. Hepatic iron content and the risk of Staphylococcus aureus bacteremia in liver transplant recipients. Prog Transplant. 2007; 17: 332-336. (Pubitemid 350250443)
119. O'Glasser AY, Scott DL, Corless CL et al. Hepatic and cardiac iron overload among patients with end-stage liver disease referred for liver transplantation. Clin Transplant. 2010; 24: 643-651.
120. Fenton H, Torbenson M, Vivekanandan P, et al. Marked iron in liver explants in the absence of major hereditary hemochromatosis gene defects: a risk factor for cardiac failure. Transplantation. 2009; 87: 1256-1260.
121. Raszeja-Wyszomirska J, Kurzawski G, Zawada I, et al. HFE gene mutations in patients with alcoholic liver disease. A prospective study from northwestern Poland. Pol Arch Med Wewn. 2010; 120: 127-131.
122. Chow JK, Werner BG, Ruthazer R, Snydman DR. Increased serum iron levels and infectious complications after liver transplantation. Clin Infect Dis. 2010; 51: e16-23.
123. Bardet V, Junior AP, Coste J, et al. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors. Liver Transpl. 2006; 12: 1649-1654. (Pubitemid 44742544)
124. Bohne F, Martínez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest. 2012; 122: 368-382.
125. Misra S, Moore TB, Ament ME, et al. Profile of anemia in children after liver transplantation. Transplantation. 2000; 70: 1459-1463.
126. Atassi T, Thuluvath PJ. Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol. 2003; 37: 72-73. (Pubitemid 36734338)
127. Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: etiology and management. Liver Transpl. 2004; 10: 165-173. (Pubitemid 38240113)
128. Anker SD, Comin Colet J, Filippatos G, et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Eng J Med. 2009; 361: 2436-2448.
129. Kaldara-Papatheodorou EE, Terrovitis JV, Nanas JN. Anemia in heart failure: should we supplement iron in patients with chronic heart failure? Pol Arch Med Wewn. 2010; 120: 354-360.